Table 1.

Estimated Actuarial Survival of CF LVAD - All Trial and Registry Data with Greater Than 100 CF Patients

Study	First Author	Year	Total CF	BTT	DT	1 Mo	6 Mo	12 Mo	24 Mo	36 Mo	48 Mo
Industry-Funded Trials and Related Registries

HMII BTT Trial¹⁰	Miller	2007	133	133	0	89%	75%	68%	-	-	-
HMII BTT Trial Registry¹¹	Pagani	2009	281	281	0	92%	82%	73%	-	-	-
HMII DT Trial¹²	Slaughter	2009	133	0	133	-	-	68%	58%	-	-
ADVANCE: HVAD BTT Trial¹³	Aaronson	2012	140	140	0	99%	94%	86%	-	-	-
ADVANCE: HVAD BTT Trial CAP¹⁴	Slaughter	2013	332	332	0	97%	91%	-	84%	-	-

Mutlicenter Registries

INCOR Analysis¹⁵	Schmid	2008	216	-	-	-	-	56%	43%	-	-
64 European Institutions¹⁶^*	Lahpor	2010	411	300	86	-	74%	72%	-	-	-
U of Minnesota, Pittsburgh, & Columbia¹⁷	Boyle	2011	101	86	15	77%	-	-	-	-	-
John INTERMACS¹⁸	John	2011	1496	1496	0	-	89%	85%	-	-	-
INTERMACS 2013¹⁹	Kirklin	2013	5436	3742	1694	95%	-	80%	70%	59%	47%
INTERMACS Thrombosis⁷	Kirklin	2014	6910	-	-	95%	87%	80%	69%	58%	46%

See Supplemental Material for all single-center studies or those with less than 100 continuous flow patients

^†

Study includes alternative indications for implant (e.g. bridge to decision, bridge to candidacy)

BTT=bridge to transplant; CAP=continued access protocol; CF=continuous-flow; DT=destination therapy; HMII= HeartMate II; HVAD=HeartWare ventricular assist device; INCOR=INCOR left ventricular assist device; INTERMACS=Interagency Registry for Mechanically Assisted Circulatory Support; mo=month; LVAD=left ventricular assist device